In vitro duvelisib interrupts AKT signalling within CLL cells stimulated by CD40L/IL-2/IL-10, CLL cell homing and intracellular signalling downstream of the BCR[216]. This evidence concerns the gene AKT1 and B-cell chronic lymphocytic leukemia.